TaiGen Biopharmaceuticals Holdings Limited (TPEX:4157)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
8.74
+0.02 (0.23%)
Jun 18, 2026, 1:30 PM CST
Market Cap6.22B -13.3%
Revenue (ttm)258.93M +71.0%
Net Income53.51M
EPS0.07
Shares Out 711.83M
PE Ratio124.27
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume588,927
Open8.75
Previous Close8.72
Day's Range8.70 - 8.83
52-Week Range7.44 - 16.40
Beta0.19
AnalystsStrong Buy
Price Target85.00 (+872.54%)
Earnings DateAug 21, 2026

About TPEX:4157

TaiGen Biopharmaceuticals Holdings Limited, a pharmaceutical company, develops novel therapeutics for transformative diseases worldwide. The company develops Taigexyn (Nemonoxacin), a non-fluorinated quinolone antibiotic for the treatment of bacterial infections. Its product pipeline comprises Taigexyn, which is in phase II clinical trial for the treatment of community-acquired pneumonia/diabetic foot infection; TG-1000, which is in phase III clinical trial to treat influenza A and B; TG-4318; ISM-4808 to treat CKD anemia; Furaprevir, a HCV pro... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2001
Country Cayman Islands
Stock Exchange Taipei Exchange
Ticker Symbol 4157
Full Company Profile

Financial Performance

Financial Statements